The Fox Chase Chemical Diversity Center, Inc. (FCCDC)

 

Fox Chase Chemical Diversity Center, Inc. Announces The Initiation Of A 2 Year Phase 1 SBIR Grant With The Fox Chase Cancer Center

 

Doylestown, PA. July 1, 2009 – The Fox Chase Chemical Diversity Center (FCCDC) today announced the initiation of a 2 year phase 1 SBIR grant with the Fox Chase Cancer Center (FCCC), Philadelphia, PA. FCCDC leads the effort of the grant entitled Pathogen-Specific Regulation of Protein Assembly (1 R43 AI084224-01) to discover and develop novel compounds for the inhibition of Yersinia enterocolitica via disruption of phorphobilinogen synthase assembly states through its collaboration with FCCC.